Skip to content
OpenCapital
Get started
Adaptive Biotechnologies logo

Adaptive Biotechnologies (ADPT) Q1 2026 Earnings

ADPT·Reported May 5, 2026·After market close

Adaptive Biotechnologies reported Q1 2026 revenue of $70.9M (+35.2% YoY), beat analyst consensus of $61.0M by $9.9M. Diluted EPS came in at $-0.13 (+35.0% YoY), beat the $-0.16 consensus by $0.03.

Revenue
$70.9Mbeat by $9.9M
Consensus: $61.0M
Diluted EPS
$-0.13beat by $0.03
Consensus: $-0.16
SEC

SEC Filings

Earnings release8-K · 0001193125-26-206455
Quarterly report10-Q · 0001193125-26-206546

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Adaptive Biotechnologies's Q1 2026 earnings report.

Adaptive Biotechnologies (ADPT) reported Q1 2026 earnings on May 5, 2026 after market close.

Adaptive Biotechnologies reported revenue of $70.9M and diluted EPS of $-0.13 for Q1 2026.

Revenue beat the consensus estimate of $61.0M by $9.9M. EPS beat the consensus estimate of $-0.16 by $0.03.

Compared to the same quarter a year prior, revenue grew 35.2% from $52.4M a year earlier and diluted EPS grew 35.0% from $-0.20.

You can read the 8-K earnings release (0001193125-26-206455) and the 10-Q periodic report (0001193125-26-206546) directly on SEC EDGAR. The filing index links above go to sec.gov.